RMC No. 108-2025 updates the FDA-endorsed VAT-exempt drug list for key illnesses, affecting pharmacies, healthcare firms, and corporate tax teams.

Businesses selling, importing, prescribing, purchasing, reimbursing, or accounting for qualified medicines must immediately validate their product master files, invoices, VAT treatment, and reimbursement rules against the updated VAT-exempt drug list endorsed by the Food and Drug Administration. RMC No. 108-2025 matters now because it updates the official list of medicines treated as VAT-exempt under the TRAIN Law and the CREATE Act for specific illnesses, and it supersedes earlier revenue memorandum circulars covering the same VAT-exempt drug categories until a new FDA endorsement is issued.

What RMC No. 108-2025 Changes

RMC No. 108-2025 publishes the full text of the October 16, 2025 letter from the Food and Drug Administration of the Department of Health endorsing the updated list of VAT-exempt drugs under Republic Act No. 10963, otherwise known as the TRAIN Law, and Republic Act No. 11534, otherwise known as the CREATE Act.

The practical change is straightforward but commercially important: the BIR is recognizing an updated FDA-endorsed list of VAT-exempt drugs for the illnesses covered by the circular. Businesses should not rely on older BIR issuances for these covered categories because RMC No. 108-2025 expressly states that previous revenue memorandum circulars issued on the subject are superseded, until a new update is endorsed by the FDA.

For Philippine tax compliance teams, this means the operative reference point for VAT-exempt medicines under these illness categories is now the updated FDA-endorsed list recognized through RMC No. 108-2025. The circular is particularly relevant for searches involving VAT-exempt medicines Philippines 2025, BIR VAT exemption drugs, FDA endorsed VAT-exempt drugs, TRAIN Law VAT-exempt medicines, and CREATE Act VAT exemption medicines.

Illness Categories and Number of VAT-Exempt Drugs

RMC No. 108-2025 summarizes the updated VAT-exempt drug list by illness category. The list covers cancer, diabetes, high cholesterol, hypertension, kidney disease, mental illness, and tuberculosis.

For cancer, the updated list includes 675 VAT-exempt drugs. For diabetes, the updated list includes 32 VAT-exempt drugs. For high cholesterol, the updated list includes 173 VAT-exempt drugs. For hypertension, the updated list includes 542 VAT-exempt drugs. For kidney disease, the updated list includes 154 VAT-exempt drugs. For mental illness, the updated list includes 30 VAT-exempt drugs. For tuberculosis, the updated list includes 75 VAT-exempt drugs.

These figures are important for pharmacies, hospitals, clinics, distributors, importers, HMOs, benefit administrators, accountants, and corporate purchasers because each product must be matched against the endorsed list before applying VAT-exempt treatment. The circular does not merely announce a general policy; it identifies the scope of the updated FDA-endorsed list by covered illness and by number of exempt drugs.

Who Is Most Affected

The most directly affected taxpayers are pharmacies, drugstores, hospitals, clinics, medical suppliers, pharmaceutical distributors, importers, manufacturers, and wholesalers that sell or move medicines covered by the FDA-endorsed list. Their accounting, invoicing, point-of-sale, and enterprise resource planning systems must correctly classify covered medicines as VAT-exempt where the medicine falls within the updated list.

Corporate accountants and CFOs of healthcare businesses should pay special attention because VAT classification affects invoice presentation, pricing, tax reporting, and reconciliation. A product incorrectly treated as VATable may result in overcharging the customer. A product incorrectly treated as VAT-exempt when it is not covered by the list may create tax exposure during a BIR audit.

The circular also matters to employers with medical reimbursement policies, HMOs, insurance administrators, company clinics, and employee benefit teams. When a reimbursement or benefit plan depends on whether a medicine is VAT-exempt, the updated list should be used as the reference for the covered illnesses.

Key Compliance Requirements and Deadlines

RMC No. 108-2025 is dated December 9, 2025. The FDA endorsement letter referred to in the circular is dated October 16, 2025. The circular does not state a separate future compliance deadline, transition period, or delayed effectivity date. For risk management purposes, businesses should treat the updated list as the current BIR-published reference upon issuance and publication of the circular.

Taxpayers should immediately review whether they sell, purchase, import, reimburse, or account for medicines under the seven covered illness categories. The compliance task is not limited to the tax department. It should involve operations, procurement, pharmacy management, billing, accounts receivable, accounts payable, and IT teams responsible for product coding and invoice configuration.

At the transaction level, businesses should check whether the drug is included in the updated VAT-exempt list, whether the illness category is covered, whether the sales invoice or official documentation reflects the correct VAT treatment, and whether prior system classifications were based on a revenue memorandum circular now superseded by RMC No. 108-2025.

Penalties and Audit Risk for Non-Compliance

RMC No. 108-2025 does not create a special penalty provision. It also does not state a new fine, surcharge, interest rate, or compromise penalty specific to the updated list. However, incorrect VAT treatment of medicines can still become a BIR audit issue because VAT classification affects output VAT, input VAT, invoicing, accounting entries, and tax returns.

For sellers, the main risk is misclassification. If a covered medicine remains coded as VATable, customers may be charged VAT despite the medicine being covered by the updated VAT-exempt list. If an uncovered medicine is treated as VAT-exempt, the seller may face exposure if the BIR later determines that VAT should have been imposed. For purchasers and reimbursing entities, the risk lies in relying on invoices, reimbursement schedules, or accounting classifications that do not reflect the updated BIR-published list.

Because the circular expressly supersedes previous revenue memorandum circulars on the same covered illnesses, taxpayers should not assume that older internal lists remain valid. Internal tax matrices should be refreshed and documented so the company can show that it applied RMC No. 108-2025 as the current reference.

Practical Steps for Businesses

First, identify all products in the company’s system that relate to cancer, diabetes, high cholesterol, hypertension, kidney disease, mental illness, and tuberculosis. The relevant search terms for internal review should include generic drug names, brand names, SKUs, supplier codes, and product descriptions.

Second, compare the company’s current VAT-exempt product list with the updated FDA-endorsed list recognized under RMC No. 108-2025. This should be done before the next VAT return cycle wherever possible, especially for healthcare businesses with high transaction volume.

Third, update point-of-sale systems, billing templates, ERP tax codes, product master files, and invoice mapping. A correct legal position is not enough if the cashier, billing clerk, or automated invoicing system still applies the wrong VAT code.

Fourth, preserve documentation. Tax teams should retain a copy of the internal review, the date of system update, the personnel who approved the change, and the list of products reclassified. This will be useful if the BIR later asks why a particular drug was treated as VAT-exempt.

Fifth, communicate the update to commercial and finance teams. Sales personnel should understand that VAT exemption may affect pricing. Accounting teams should know that earlier lists have been superseded. Procurement and reimbursement teams should know that the current list is based on the FDA endorsement recognized by RMC No. 108-2025.

Why This Matters for CFOs and Corporate Accountants

VAT-exempt drug classification is not merely a healthcare issue. It is a tax reporting, systems, and audit-defense issue. For CFOs and corporate accountants, the most important point is that RMC No. 108-2025 changes the controlling reference for covered VAT-exempt medicines. The numbers are substantial, particularly for cancer medicines with 675 listed drugs and hypertension medicines with 542 listed drugs.

Businesses that handle thousands of medicine transactions should not wait for an audit or customer complaint before reviewing their VAT setup. The safest approach is to perform a documented product-level review, update tax codes, and train billing personnel as soon as possible.

How Ablola, Saribong & Gueco Can Help

Ablola, Saribong & Gueco assists businesses, healthcare providers, distributors, importers, pharmacies, and corporate taxpayers in reviewing BIR issuances, VAT classifications, invoicing practices, and tax audit exposure. For RMC No. 108-2025, we can help assess whether your medicines, reimbursement policies, billing systems, and documentation are aligned with the updated VAT-exempt drug list under the TRAIN Law and CREATE Act.

For assistance with BIR compliance, VAT-exempt medicines, tax audits, invoicing rules, or healthcare-related tax issues in the Philippines, contact Ablola, Saribong & Gueco through MakatiLawFirm.com.


Leave a Comment

Your email address will not be published. Required fields are marked *